CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Replek AD Skopje Company Snapshot
Replek AD Skopje operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Replek AD Skopje with three other pharmaceutical manufacturers in Europe: Calliditas Therapeutics AB of SWEDEN (2019 sales of 184.83 million Swedish Kronor [US$20.89 million] of which 100% was Operations), Vistin Pharma ASA of NORWAY (227.19 million Norwegian Kroner [US$24.48 million] ), and Dbv Technologies which is based in FRANCE (13.14 million Euros [US$15.46 million] of which 100% was research and development of epicutaneous).

Sales Analysis. Replek AD Skopje reported sales of 1.05 billion Macedonian Denars (US$19.98 million) for the year ending December of 2019. This represents an increase of 7.6% versus 2018, when the company's sales were 974.74 million Macedonian Denars. This was the fourth straight year of sales growth at Replek AD Skopje. The sales level in 2019 was fairly close to the level five years ago: in 2014, Replek AD Skopje had sales of 1.11 billion Macedonian Denars.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Replek AD Skopje
  Stock Performance Chart for Replek AD Skopje
 
  Stock Data: Recent Stock Performance:
  Current Price (8/12/2020): 85,000
(Figures in Macedonian Denars)
1 Week n/a   13 Weeks n/a  
4 Weeks n/a   52 Weeks n/a  
 
Replek AD Skopje Key Data:
  Ticker: REPL Country: Macedonia
  Exchanges: MAC Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2019 Sales 1,049,032,000
(Year Ending Jan 2020).
Employees: 352
  Currency: Macedonian Denars Market Cap: 2,203,200,000
  Fiscal Yr Ends: December Shares Outstanding: 25,920
  Share Type: Closely Held Shares: 13,733
 
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.